About Admetsys
Admetsys has developed a first-of-its-kind artificial pancreas for hospital and surgical care, leveraging
adaptive learning algorithms and counterbalancing treatment of insulin and glucose.
97% Control
between 80-125 mg/dL
0% Hypoglycemia
< 70 mg/dL
2.5 hrs Mean Time
to Normoglycemia
Nurses:
Frequent measures are critical for a clear glycemic picture.
In one retrospective study, average
frequency was 2.6 hours despite
a goal of hourly checks.
A 12-minute measurement delay (from hourly)
was associated with 67% of severe
hypoglycemia episodes.
86% of nurses in one study felt that an easier or more automated
form of measurement was needed.
Administrators:
Proper diabetic control:
Lowers Legal
& Regulatory Risk
Lowers Costs
Increases
Standard of Care
Improves
Reimbursement Rates
Contact Us
Want to get involved and be a part of Admetsys?
Join us as an Advocate, Advisor or Investor.
We'll never send you spam.
We hate spam.
Stay tuned.
Diabetic treatment.
Revolutionized.
For people at diabetic risk, glucose control is at its most
crucial while in hospital or surgery. Correcting abnormal
glucose levels and keeping them normal speeds recovery,
prevents infection, and reduces complications. To date,
this has been difficult, highly labor-intensive, and imprecise.
That is about to change.
Admetsys has conducted 3 clinical trials with outstanding results:
Watch the video to Learn More
PHYSICIANS
ABOUT
NURSES
ADMINISTRATORS
INVESTORS
CONTACT US
Source: American Diabetes Association (ADA).
® ™ © 2019 Admetsys. All Rights Reserved. Admetsys™, Metabolic Autopilot™ and Smart Pancreas™ are trademarks of Admetsys.
Device not yet cleared for commercial sale. Limited in the USA to investigational use.
